Previously disclosed buy-backs 0 n.a. n.a.

on November 14, 2024 at 6:00 pm Dubai time / 3:00 pm Oslo time. Dial-in details for the call are included in the press release posted on November 6, 2024 and on page 2 of this release.

Scientific progress in ACLF to be featured at The Liver Meeting® 2024, with 4 posters presenting new preclinical data, and 3 events bringing together key ACLF stakeholders Results from UNVEIL-IT® ...

556,500 shares in the Company, by way of donation/gift of 100% of the share capital in Sea Shell Enterprises Limited to members of his family. Following the transactions, Themistoklis Alafouzos will ...

insiders in the Company was incorrect. Please see updated version below.

- Svein Oskar Stoknes has acquired 1,400 shares. Mr. Stoknes' total shareholding in Aker after the acquisition will be 11,400 shares. - Lene Landøy has acquired 1,000 shares. Mrs. Landøy's total ...

issue of between 107,382,966 to 150,000,000 new shares in the Company, (the "Rights Issue"), of which an underwriting consortium (jointly the "Underwriters") agreed to underwrite subscription of new ...

shareholders, at a fixed subscription price of NOK 3 per New Share (the "Private ...

3:00 pm Oslo time. Dial-in details for the call are included in the press release posted on November 6, 2024 and on page 3 of this release.

Book-to-bill above 1 and sales organic growth around 5% aEBIT margin around 6.5% Free Cash Flow within the range €300 million to €500 million 13 November 2024 – In the first half of fiscal year ...

Crossject successfully completes a new U.S. summative human factors study to assess the usability of ZENEO® Midazolam, soon to be commercialized globally as ZEPIZURE®, under simulated chemical attack ...

Reference is made to the notice of a letter of award for the provision of a ...